Ratings Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Market Closed - Swiss Exchange Other stock markets 11:31:35 2024-06-07 am EDT			5-day change	1st Jan Change
268.8 ^CHF	+1.28%		+6.33%	+2.83%

Jun. 07	Roche: efficacy of Evrysdi in spinal muscular atrophy	CF
Jun. 07	Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Sales forecast by analysts have been recently revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With an enterprise value anticipated at 3.43 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ROCHE HOLDING AG	+2.83%	219B	-
ELI LILLY AND COMPANY	+45.82%	765B	C+
JOHNSON & JOHNSON	-6.16%	354B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	299B	C+
ASTRAZENECA PLC	+18.45%	248B	B+
NOVARTIS AG	+11.88%	216B	B-
AMGEN INC.	+5.90%	164B	C+
PFIZER, INC.	-0.73%	162B	C+
SANOFI	+1.53%	123B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes